Edition:
United States

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

6.00USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$6.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
84,156
52-wk High
$6.65
52-wk Low
$1.34

Latest Key Developments (Source: Significant Developments)

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 08:30am EST 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors
Tuesday, 21 Nov 2017 08:30am EST 

Nov 21 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors.Pieris Pharmaceuticals Inc - ‍Geraghty replaces Chau Khuong, who is stepping down from board​.  Full Article

Pieris Pharmaceuticals reports Q3 loss per share $0.16
Wednesday, 8 Nov 2017 04:30pm EST 

Nov 8 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update.Q3 loss per share $0.16.Pieris Pharmaceuticals Inc - ‍cash and equivalents totaled $89.9 million as of September 30, 2017, compared to $29.4 million as of December 31, 2016​.  Full Article

Sichuan Kelun Pharmaceutical unit signs license agreement with Pieris Pharmaceuticals
Thursday, 10 Aug 2017 06:48am EDT 

Aug 10(Reuters) - Sichuan Kelun Pharmaceutical Co Ltd <002422.SZ>:Says its Sichuan-based unit signs license agreement with Pieris Pharmaceuticals Inc <<>>, regarding a patent of tumour immunotherapy .Says the unit grants Pieris Pharmaceuticals to use the license to develop and produce related products.Says Pieris Pharmaceuticals needs to pay milestone payments up to $94 million to the unit in development and sales and to pay sales commissions to the unit .  Full Article

Pieris Pharmaceuticals Q2 loss per share $0.23
Wednesday, 9 Aug 2017 05:20pm EDT 

Aug 9 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals reports financial results for the second quarter ended June 30, 2017 and provides corporate update.Q2 loss per share $0.23.Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

T2 Biosystems names Darlene Deptula-Hicks as CFO
Monday, 1 May 2017 09:00am EDT 

May 1 (Reuters) - T2 Biosystems Inc : :T2 Biosystems names Darlene Deptula-Hicks as chief financial officer.Deptula-Hicks was most recently CFO and senior vice president at Pieris Pharmaceuticals Inc.T2 Biosystems Inc - Deptula-Hicks was most recently CFO and senior vice president at Pieris Pharmaceuticals Inc.  Full Article

Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska pharmaceutical
Monday, 27 Feb 2017 07:30am EST 

Pieris Pharmaceuticals Inc : Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska Pharmaceutical . Pieris Pharmaceuticals Inc - co will receive an immediate option payment of $2.75 million usd from Aska . Pieris Pharmaceuticals Inc - a Phase 1 study conducted in healthy volunteers demonstrated that a single dose of PRS-080 was well tolerated . Pieris Pharmaceuticals Inc - Pieris may also receive double-digit royalties on net sales of PRS-080 up to mid- to high-teens . Pieris Pharmaceuticals Inc - PRS-060, anticipated to begin a first-in-human study around middle of 2017 . Pieris Pharmaceuticals Inc - PRS-343 scheduled to enter a first-in patient trial in first half of 2017 .Pieris Pharmaceuticals - should Aska exercise option, Pieris would be eligible for over $80 million usd in combined option exercise fee and milestones.  Full Article

Pieris announces management transition
Tuesday, 7 Feb 2017 05:21pm EST 

Pieris Pharmaceuticals Inc : Pieris announces management transition . Pieris Pharmaceuticals Inc - Lance Thibault of Danforth Advisors, is assuming role of acting Chief Financial Officer . Pieris Pharmaceuticals Inc - Darlene Deptula-Hicks has submitted her resignation, effective today, to pursue other interests .Pieris Pharmaceuticals Inc - Pieris also announced termination of its atm common stock sales agreement, originally entered into on October 5, 2016.  Full Article

Pieris Pharma says entered into a sales agreement with Cowen and Co
Wednesday, 5 Oct 2016 05:51pm EDT 

Pieris Pharmaceuticals Inc : Under agreement co may offer, sell shares of stock, par value $0.001 per share an offering price of up to $35 million through Cowen .Says entered into a sales agreement with Cowen And Company - SEC filing.  Full Article

Pieris Pharmaceuticals files for mixed shelf of up to $100 mln- sec filnig
Friday, 3 Jun 2016 05:25pm EDT 

Pieris Pharmaceuticals Inc :Files for mixed shelf of up to $100 million - sec filnig.  Full Article

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402